NCT07718867Not yet recruiting
Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, China
Effectiveness and Cost-Effectiveness of Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, Yunnan, China: A Cluster Randomised Controlled Trial
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
This project aims to compare Point-of-care capillary HbA1c (POC-cHbA1c) testing and fingerstick random blood glucose (RBG) testing in terms of type 2 diabetes detection rate and cost-effectiveness, in order to optimise current screening strategies for rural populations at high risk of diabetes in rural Dali, China, and to improve treatment adherence and self-management among people with diabetes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 720 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 28 Jul 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- The University of Hong Kong
- Diseases
- Type 2 diabetes
- NCT number
- NCT07718867
What you commit to
- Study type: Interventional
- Planned participants: 720
- From 28 Jul 2026 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active thyroid disease or other active endocrine disorders at recruitment, such as Cushing's syndrome or acromegaly;
- Known haemoglobinopathy, severe anaemia, recent acute blood loss, or history of blood transfusion or blood donation within the past three months;
Lab values
- Known history of T2DM or currently receiving glucose-lowering treatment;
- HbA1c testing with a clear result within the past three months, or completion of standardised diabetes screening within the past six months;
- Currently receiving treatment that may substantially affect interpretation of HbA1c, such as erythropoietin therapy or recent high-dose iron therapy.
Other
- Pregnant or breastfeeding at the time of recruitment;
Who the study is looking for
- Aged 18 years or above;
- Permanent residents of Dali City who have lived locally for at least six consecutive months;
- Registered as rural residents;
- No known history of diabetes;
- Meet at least one of the high-risk criteria for T2DM specified in the Chinese Guidelines for the Prevention and Treatment of Diabetes issued by the Chinese Diabetes Society;
- Able to understand the study information and provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First People's Hospital of Dali Coordinator of this site? Confirm its status | Dali | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.